Alzinova: Positive Pre-IND meeting with FDA - Redeye

Redeye leaves a note following Alzinova's update regarding its Pre-IND meeting with the FDA. We are encouraged to learn that the company has received positive feedback on the planned clinical development program for vaccine candidate ALZ-101.

Länk till analysen i sin helhet: https://www.redeye.se/research/928949/alzinova-positive-pre-ind-meeting-with-fda?utm_source=finwire&utm_medium=RSS